Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1

AstraZeneca

27 September 2022 - First medicine approved in Japan to treat this rare and debilitating genetic condition.

Koselugo (selumetinib) has been approved in Japan for the treatment of paediatric patients three years of age and older with plexiform neurofibromas in neurofibromatosis type 1 with clinical symptoms, such as pain and disfigurement, and plexiform neurofibromas which cannot be completely removed by surgery without risk of substantial morbidity.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Paediatrics , Japan